Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland
- Research Interests
Professor Kairemo graduated with a M.Sc.(Eng) degree from Helsinki University of Technology in 1980 before undertaking medical training at the University of Helsinki. He undertook specialist training in Clinical Chemistry, Nuclear Medicine, Health Care Administration and Clinical Pharmacology at Helsinki University Central Hospital and then a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center from 1989-93. Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). Since 2009, he has been Chief of Nuclear Medicine and Molecular Radiotherapy at the Docrates Cancer Center, in Helsinki. Prof Kairemo has also held posts in industry, as Medical Director of Cancer Targeting Technologies (2001-6), Medical Director of Imanext Ltd (2006-8) and Clinical Director at Advanced Accelerator Applications, a joint French-Italian initiative. Prof Kairemo has wide experience in the development of tumour-seeking compounds, including monoclonal antibodies, specific phage-display peptides and cytotoxic drugs, and he has coordinated several EU Research Programme proposals, including as the National Coordinator and Management Committee Member for the European Union COST Action Project (BM 0607, Targeted Radionuclide Therapy) from 2007-11. Besides a few patents, Prof. Kairemo has published more than 150 original articles in peer-reviewed journals. Recently he received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and was President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Finnish Lapland.